This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
After spinning out Speedel (cardiovascular and metabolic diseases) in 1998, Novartis is buying back the now-public company. Novartis has raised its current 9.7% equity stake to 61.4% through the acquisition of about 4mm registered shares from five major shareholders, including company CEO Alice Huxley who held a 21.5% stake. The investors received a total of CHF525.4mm ($509mm) or about CHF130 per share (a 98% premium).
Payment Includes Cash
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?